Pharmacological gating modulation of small- and intermediate-conductance Ca2+ -activated K+ channel (KCa2.x and KCa3.1)

Palle Christophersen, Heike Wulff

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

This short review discusses pharmacological modulation of the opening/closing properties (gating) of small- and intermediate-conductance Ca2+-activated K+ channels (KCa2 and KCa3.1) with special focus on mechanisms-of-action, selectivity, binding sites, and therapeutic potentials. Despite KCa channel gating-modulation being a relatively novel field in drug discovery, efforts in this area have already revealed a surprising plethora of pharmacological sites-of-actions and channel subtype selectivity exerted by different chemical classes. The currently published positive modulators show that such molecules are potentially useful for the treatment of various neurodegenerative disorders such as ataxia, alcohol dependence, and epilepsy as well as hypertension. The negative KCa2 modulators are very effective agents for atrial fibrillation. The prediction is that further unraveling of the molecular details of gating pharmacology will allow for the design of even more potent and subtype selective KCa modulators entering into drug development for these indications.

Original languageEnglish (US)
Pages (from-to)336-343
Number of pages8
JournalChannels
Volume9
Issue number6
DOIs
StatePublished - Jan 1 2015

Fingerprint

Calcium-Activated Potassium Channels
Modulators
Modulation
Pharmacology
Drug Discovery
Ataxia
Neurodegenerative Diseases
Atrial Fibrillation
Alcoholism
Epilepsy
Binding Sites
Alcohols
Hypertension
Molecules
Pharmaceutical Preparations
Therapeutics

Keywords

  • Ca -activated K channel
  • CyPPA
  • IK channel
  • K2
  • K3.1
  • NS309
  • SK channel
  • SKA-121
  • SKA-31

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Pharmacological gating modulation of small- and intermediate-conductance Ca2+ -activated K+ channel (KCa2.x and KCa3.1). / Christophersen, Palle; Wulff, Heike.

In: Channels, Vol. 9, No. 6, 01.01.2015, p. 336-343.

Research output: Contribution to journalReview article

@article{04d12ee197d1478da36632467760ad30,
title = "Pharmacological gating modulation of small- and intermediate-conductance Ca2+ -activated K+ channel (KCa2.x and KCa3.1)",
abstract = "This short review discusses pharmacological modulation of the opening/closing properties (gating) of small- and intermediate-conductance Ca2+-activated K+ channels (KCa2 and KCa3.1) with special focus on mechanisms-of-action, selectivity, binding sites, and therapeutic potentials. Despite KCa channel gating-modulation being a relatively novel field in drug discovery, efforts in this area have already revealed a surprising plethora of pharmacological sites-of-actions and channel subtype selectivity exerted by different chemical classes. The currently published positive modulators show that such molecules are potentially useful for the treatment of various neurodegenerative disorders such as ataxia, alcohol dependence, and epilepsy as well as hypertension. The negative KCa2 modulators are very effective agents for atrial fibrillation. The prediction is that further unraveling of the molecular details of gating pharmacology will allow for the design of even more potent and subtype selective KCa modulators entering into drug development for these indications.",
keywords = "Ca -activated K channel, CyPPA, IK channel, K2, K3.1, NS309, SK channel, SKA-121, SKA-31",
author = "Palle Christophersen and Heike Wulff",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/19336950.2015.1071748",
language = "English (US)",
volume = "9",
pages = "336--343",
journal = "Channels",
issn = "1933-6950",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - Pharmacological gating modulation of small- and intermediate-conductance Ca2+ -activated K+ channel (KCa2.x and KCa3.1)

AU - Christophersen, Palle

AU - Wulff, Heike

PY - 2015/1/1

Y1 - 2015/1/1

N2 - This short review discusses pharmacological modulation of the opening/closing properties (gating) of small- and intermediate-conductance Ca2+-activated K+ channels (KCa2 and KCa3.1) with special focus on mechanisms-of-action, selectivity, binding sites, and therapeutic potentials. Despite KCa channel gating-modulation being a relatively novel field in drug discovery, efforts in this area have already revealed a surprising plethora of pharmacological sites-of-actions and channel subtype selectivity exerted by different chemical classes. The currently published positive modulators show that such molecules are potentially useful for the treatment of various neurodegenerative disorders such as ataxia, alcohol dependence, and epilepsy as well as hypertension. The negative KCa2 modulators are very effective agents for atrial fibrillation. The prediction is that further unraveling of the molecular details of gating pharmacology will allow for the design of even more potent and subtype selective KCa modulators entering into drug development for these indications.

AB - This short review discusses pharmacological modulation of the opening/closing properties (gating) of small- and intermediate-conductance Ca2+-activated K+ channels (KCa2 and KCa3.1) with special focus on mechanisms-of-action, selectivity, binding sites, and therapeutic potentials. Despite KCa channel gating-modulation being a relatively novel field in drug discovery, efforts in this area have already revealed a surprising plethora of pharmacological sites-of-actions and channel subtype selectivity exerted by different chemical classes. The currently published positive modulators show that such molecules are potentially useful for the treatment of various neurodegenerative disorders such as ataxia, alcohol dependence, and epilepsy as well as hypertension. The negative KCa2 modulators are very effective agents for atrial fibrillation. The prediction is that further unraveling of the molecular details of gating pharmacology will allow for the design of even more potent and subtype selective KCa modulators entering into drug development for these indications.

KW - Ca -activated K channel

KW - CyPPA

KW - IK channel

KW - K2

KW - K3.1

KW - NS309

KW - SK channel

KW - SKA-121

KW - SKA-31

UR - http://www.scopus.com/inward/record.url?scp=84964047827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964047827&partnerID=8YFLogxK

U2 - 10.1080/19336950.2015.1071748

DO - 10.1080/19336950.2015.1071748

M3 - Review article

C2 - 26217968

AN - SCOPUS:84964047827

VL - 9

SP - 336

EP - 343

JO - Channels

JF - Channels

SN - 1933-6950

IS - 6

ER -